Patient 1 at ages 9 years (A) and 29 years (B), patient 2 at ages 3½ years (C) and 21 years (D), and patient 3 at ages 2 years (E) and 14 years (F).
DNA sequence analysis of the GNS gene. The top tracings show normal wild-type GNS genomic DNA sequences from a control, and the bottom tracings show GNS genomic DNA sequences from a proband. The corresponding nucleotide sequence and 3-letter amino acid code are shown above each tracing. A, The proband from family 1, whose genomic DNA sequence was homozygous for a T nucleotide in the first position of codon 390, predicting translation of a premature termination (p.Gln390Ter). B, Heterozygosity for the c.876-2A>G splice mutation in the proband from family 2. The direction of sequencing is from 3′ to 5′. C, The position of the 5–base pair insertion into the normal nucleotide sequence of exon 10; the lines demarcate the boundaries of the inserted sequence in the mutated GNS gene from the proband of family 3. Arrows indicate the mutation (A and B, red spike; C, 5 spikes indicated by the 2 lines).
Jansen ACM, Cao H, Kaplan P, Silver K, Leonard G, De Meirleir L, Lissens W, Liebaers I, Veilleux M, Andermann F, Hegele RA, Andermann E. Sanfilippo Syndrome Type DNatural History and Identification of 3 Novel Mutations in the GNS Gene. Arch Neurol. 2007;64(11):1629-1634. doi:10.1001/archneur.64.11.1629
Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007
Mucopolysaccharidosis type IIID (MPS-IIID), or Sanfilippo syndrome type D, is a rare autosomal recessive lysosomal storage disorder caused by mutations in the N-acetylglucosamine-6-sulfatase (GNS) gene, leading to impaired degradation of heparan sulfate.
To report the natural history of MPS-IIID in 2 siblings described by Kaplan and Wolfe in 1987 and to study the phenotype in 2 other unrelated families with MPS-IIID.
Design, Setting, and Patients
Case series of 4 patients with MPS-IIID: 2 siblings followed up at the Montreal Neurological Hospital and Institute, 1 patient followed up at the UZ Brussel, and 1 patient recruited through the prenatal counseling program at the UZ Brussel.
Main Outcome Measures
Clinical and molecular data collected from 3 families with enzyme-based diagnosis of MPS-IIID.
The course of the disease was characteristic of MPS-IIID in all patients, although survival may be longer than was previously reported. In family 1, both siblings were homozygous for a novel nonsense mutation in the GNS gene (c.1168C>T). In family 2, the proband carried a heterozygous mutation occurring in a splice recognition site in the intron 7 boundary (c.876-2A>G). The second mutation in this patient remains to be identified. In family 3, the proband was homozygous for a novel frameshift mutation in GNS due to the insertion of 5 nucleotides (c.1138_1139insGTCCT).
Major issues in the care of patients with MPS-IIID include behavioral problems, sleep problems, recurrent infections, dysphagia, and pain from orthopedic complications. To date, all mutations in GNS predict protein truncation, and there is no obvious genotype-phenotype correlation.
Mucopolysaccharidosis type III (MPS-III), or Sanfilippo syndrome, is a group of lysosomal storage disorders caused by impaired degradation of heparan sulfate. Four subtypes have been defined, each caused by deficiency of a different enzyme: heparan N-sulfatase (type A), α-N-acetylglucosaminidase (type B), acetyl coenzyme A:α-glucosaminide acetyltransferase (type C), and N-acetylglucosamine-6-sulfatase (type D; Online Mendelian Inheritance in Man [OMIM] 252940).1 Compared with the other MPSs, Sanfilippo syndrome is characterized by severe central nervous system degeneration and relatively mild somatic disease.2 The first symptoms usually manifest between 2 and 6 years of age, severe neurologic degeneration generally occurs between 6 and 10 years of age, and death typically occurs during the second or third decade of life.3 Type A has been reported to be the most severe, with earlier onset, rapid progression of symptoms, and shorter survival, but there is considerable intratype variation.2
The enzymatic defect in MPS-IIID was defined by Kresse et al4 in skin fibroblasts of 2 patients, 1 of East Indian descent and 1 of Sardinian origin. The phenotypes of 17 patients with Sanfilippo syndrome type D have been reported in the literature (Table)5- 14: 11 patients in 8 families originated from Italy,5- 8,14 1 from the Netherlands,9 1 from Saudi Arabia,10 1 from Poland,12 and 1 from Pakistan,13 and the remaining 2 were white not otherwise specified.11
An autosomal recessive disorder, MPS-IIID is caused by mutations in the GNS gene (14 exons) on chromosome 12q14, which encodes N-acetylglucosamine-6-sulfatase.16,17 To date, only 4 mutations, c.1169delA,13 c.1063C>T,15 c.814C>T,14 and a large intragenic deletion,14 have been reported in patients with Sanfilippo syndrome type D. We report 3 novel mutations in the GNS gene and clinical follow-up of the 2 siblings described by Kaplan and Wolfe in 19877 as well as the phenotypes of 2 other unrelated families with MPS-IIID.
Detailed medical and family histories were obtained for 2 of the families. Patients were examined, and medical records were reviewed. The third family was identified through a prenatal counseling program, and clinical information was limited. Blood samples were collected for genetic studies. Genomic DNA was isolated using a DNA isolation kit (Puregene; Gentra Systems Inc, Minneapolis, Minnesota), according to the manufacturer's instructions. Amplification of coding regions and intron-exon boundaries of GNS from genomic DNA was performed using the primers and conditions described previously.15 Polymerase chain reaction products were purified and directly sequenced in both directions (ABI Prism 3730; PE Applied Biosystems, Mississauga, Ontario, Canada). Each mutation was confirmed using an independent sequencing reaction on another day. Control subjects were genotyped for each mutation using dedicated allele-specific detection methods (details of reagents and conditions are available on request). The DNA analysis protocol was approved by the ethics review panel of the University of Western Ontario.
In this family, both parents originated from a small community in Abruzzo, Italy, but were unaware of any consanguinity despite the fact that the maternal grandmother had the same surname as the father.
The proband, a 31-year-old man, presented with developmental delay at age 2 years (Figure 1A). He started saying single words at age 3 years and phrases at age 4 years. He started school in a regular kindergarten, had to repeat grade 2, and later required special education. The diagnosis of Sanfilippo syndrome type D was suspected at age 8 years because of excess amounts of urinary heparan sulfate, and it was confirmed at age 9 years based on the complete absence of N-acetylglucosamine-6-sulfatase activity in fibroblasts. He had surgery for left pes cavus deformity at ages 12 and 19 years and for a pilonidal sinus tract at age 17 years. During adolescence he had severe oppositional behavior, and school performance regressed. He had increasing difficulties walking beginning at age 25 years and gradually became wheelchair bound. Sleep problems have occurred from time to time but have never been a major burden. He sometimes had periods of restless sleep with frequent awakenings, and he recently had an inverted sleep-wake cycle for 3 weeks. At age 28 years, he was investigated for brief episodes characterized by holding his head, followed by facial redness, drooling, and crying. No changes were recorded on continuous video electroencephalography during these events. There was no hydrocephalus.
At age 31 years he understands simple commands; he moans or screams to draw attention, but he does not talk. He has a quiet nature and, despite limited communication, a good relationship with his brother and parents. He is fully dependent for dressing, eating, and personal hygiene. He has dysphagia for liquids and needs to be spoon-fed. He has low-set ears, coarse facial features, a short prominent forehead, deep-set eyes, hypertrichosis of the eyebrows, synophrys, a low nasal bridge, anteverted nares, and thick lips with a wide alveolar ridge. He has a short neck, broad hands and feet with short blunt fingers and toes, fixed contractures of the elbows and heel cords, and bilateral pes cavus (Figure 1B). His vision is reduced and he has night blindness. Deep tendon reflexes are brisk and equal bilaterally. The plantar responses are equivocal. Sensory deficits cannot be assessed because of poor cooperation. He can stand very briefly unassisted. He can walk with difficulty with bilateral support.
His 23-year-old brother was diagnosed in infancy based on family history, clinical features, and elevated levels of MPS in the urine (Figure 1C). Elbow contractures were noted in the first year of life. Development slowed after age 1 year, and his facial features coarsened. He started kindergarten in a regular school, but he was transferred to special education at age 7 years. He had recurrent otitis media treated with tympanostomy tubes and tonsillectomy.
In his late teens, the predominant problems were behavioral, with agitation, hyperactivity, and occasional fugue, for which he was treated with risperidone and procyclidine hydrochloride for 6 months without any improvement. Between ages 18 and 22 years, he had severe sleep problems characterized by frequent awakenings. He would get up at night and wander around the house, and he experienced much difficulty in getting to sleep again. Treatment with benzodiazepines resulted in increased daytime somnolence. Since age 20 years, he has had increasing drooling, with abundant mucus secretions, and dysphagia, mainly for liquids, which was a major cause of morbidity. Drooling and dysphagia improved markedly with botulinum toxin injections in the salivary glands.
At age 23 years, he has progressive hearing loss. He can dress with some supervision and needs help with personal hygiene. He is good-humored and has an outgoing nature. He is dysarthric, uses simple words, and understands simple commands. He has a prominent forehead and occiput, coarse facial features, thick eyebrows with hypertrichosis, a flat nasal bridge, a wide mouth, a short neck, moderate thoracic scoliosis, and fixed contractures of the elbows and heel cords (Figure 1D). He experiences increasing difficulty getting up from a chair but can still run quickly. Deep tendon reflexes are present and brisk bilaterally. There are no cerebellar signs. Neurosensory tests are noncontributory. He has a cardiac systolic ejection murmur.
When the brothers were 29 and 21 years of age, respectively, formal neuropsychological testing could not be performed, but full IQ scores were estimated to be below 50. On the basis of previous evidence from school records and early drawings, it was evident that their IQ scores had been significantly higher.
Genomic DNA analysis showed that both brothers were homozygous for a single nucleotide change in exon 10, designated c.1168C>T, which predicted a nonsense mutation at the amino acid level in residue 390, namely, glutamine (CAG) to a stop codon (TAG) or p.Gln390Ter (Figure 2A). The DNA sequence analysis subsequently showed that each parent was heterozygous for the c.1168C>T mutation. The mutation was absent from 200 chromosomes of healthy individuals.
The proband, a 15-year-old boy, is the third child of healthy, nonconsanguineous parents of Belgian origin (Figure 1E). Early developmental milestones were normal, but at age 5 years delayed psychomotor development with severe speech delay was diagnosed, and speech therapy and physiotherapy were initiated. Surgery for bilateral inguinal hernia was performed at age 2½ years. He had recurrent upper respiratory tract infections, for which he received bilateral tympanostomy tubes at ages 2 and 3½ years and tonsillectomy at age 5 years. He was diagnosed as having Sanfilippo syndrome type D at age 6 years based on elevated levels of urinary MPS and the complete absence of N-acetylglucosamine-6-sulfatase activity in fibroblasts. Sleep problems, behavioral problems, and pain from hip dysplasia have been the major causes of morbidity in this patient. Sleep problems started at age 5 years and were characterized by difficulty falling asleep, frequent awakenings, and restless sleep and were treated successfully with melatonin from age 8 years until age 14 years. He then became very agitated at night and would sleep for only 4 to 5 hours. Melatonin was replaced by lormetazepam, 1 mg/d, with good results. Behavioral problems included restlessness, hyperactivity, and aggressive outbursts and were a significant burden for the family. Trials with lorazepam, prazepam, pipamperone, risperidone, melitracen hydrochloride, and flupentixol had little effect. Valgus position and epiphyseal dysplasia of the hips caused severe pain and required bilateral osteotomy at age 11 years. The postoperative course was complicated by wound infection, increased speech problems, swallowing problems that required tube feeding, and severe behavioral problems, for which he received sedation during several weeks. He gradually recovered his preoperative level of functioning, but he continued to have pain in both hips that required continuous treatment with nonsteroidal anti-inflammatory drugs and local infiltrations with analgesics. At age 15 years, the osteosynthesis material (plate and screws) had to be removed from the femur because of pain and scarring of the overlying skin. The surgery was complicated by unilateral osteomyelitis. Six months later, he had a luxation of the left hip that required removal of the femoral head. He had multiple infections and needed a percutaneous endoscopic gastrostomy tube for feeding.
At age 15½ years he is dysarthric, uses simple words, and understands simple commands. He does not like to be touched, but he holds on to every person who comes close. In the past 2 years, he has lost any form of occupation or play but remains good-humored when comfortable. He has coarse features closely resembling those of the siblings described in family 1, short stature, and bilateral pes cavus (Figure 1F). Stretch responses are present and equal bilaterally. Sensory functions are impossible to assess. He is wheelchair bound and is fully dependent for all activities of daily living.
Magnetic resonance imaging of the brain at age 15 years showed severe corticosubcortical atrophy and more discrete cerebellar atrophy. Electroencephalograms showed slow background activity of low voltage. Continuous 24-hour video electroencephalographic monitoring was performed at age 14 years because of episodes of holding the head and crying for 15 minutes, similar to what was described in the first patient. No epileptiform changes were recorded. Evoked potentials were normal. He has fusion of the vertebral bodies of C2 and C3, hypoplasia of the vertebral bodies of C4 to C7, a discrete insufficiency of the mitral valve, and hepatosplenomegaly. Results of the ophthalmologic examination at age 10 years were normal.
Mutation analysis of the GNS gene revealed a heterozygous mutation in a splice recognition site in the intron 7/exon 8 boundary, namely, c.876-2A>G (Figure 2B). The mutation was absent from 200 chromosomes of control subjects. The patient was also heterozygous for a previously described single nucleotide polymorphism (c.198A/G) in exon 2.17 A second potential disease-causing mutation could not be found. The unaffected mother was heterozygous for the same 2 DNA changes.
The proband is a 15-year-old girl of Turkish-English descent who was diagnosed as having Sanfilippo syndrome type D at age 13 years based on the phenotype, positive MPS screen in the urine, and enzyme assessment. She is severely retarded and is fully dependent for all activities of daily living.
She was homozygous for a novel 5–base pair insertion in exon 10, c.1138_1139insGTCCT, resulting in a frameshift starting from codon 380 and in premature termination of the protein at amino acid position 389 (p.Asp380GlyfsX9) (Figure 2C). The mutation was absent from 200 chromosomes of control subjects.
Mutations in the GNS gene result in the rare lysosomal storage disorder Sanfilippo syndrome type D. There is no effective treatment for the disorder: bone marrow transplantation in a presymptomatic patient with MPS-IIIA18 and enzyme replacement in the caprine model for MPS-IIID19 did not result in any change in the neurologic features of the disease. Reports on the natural history of MPS-IIID are scarce and, unlike for Fabry or Hunter disease, a systematic follow-up registry does not exist. The disease evolution in all 4 patients has followed the classic pattern of Sanfilippo syndrome.
Sleep problems are common in patients with MPS-III20 and are characterized by sleep maintenance insomnia with frequent nocturnal awakenings and by an extremely irregular sleep pattern on polygraphic recordings.21 Sleep problems were present in all 3 patients described herein on whom information was available. Treatment with benzodiazepines often results in increased daytime somnolence,22 as was reported in patient 2. Melatonin is the treatment of choice23 and was applied successfully in patient 3. Evidence of the implication of melatonin in the pathogenesis of sleep problems in Sanfilippo syndrome has been provided by Guerrero et al,24 who demonstrated an alteration in the circadian rhythm of melatonin in patients with Sanfilippo syndrome.
Behavioral problems proved to be extremely difficult to treat and were a major cause of distress for the families. Recurrent infections and pain often led to episodic regression in general functioning, affecting mobility, speech, swallowing, and behavior. Life expectancy in patients with Sanfilippo type D was found to be longer compared with that of patients with type A, illustrating intratype variability.2
The brothers in family 1 are the oldest patients with MPS-IIID described to date, with survival into the fourth decade for patient 1. The rate of disease progression in this family seems more benign compared with that in families 2 and 3 and other patients with MPS-IIID described in the literature (life expectancy of 14 and 17 years reported by Jones et al11). This is consistent with previous reports on clinical heterogeneity in MPS-IIID.6 This intratype variability may be related to multiple factors, including the nature of the mutation or differences in the care that the patients have received. Survival into adulthood requires a well-orchestrated transition from pediatric to adult care. In everyday practice, parents of children with special needs often experience a gap between pediatric and adult care, and in family 1 this has added significant stress to the care of the siblings.
Comparing the phenotypic features of all reported patients with MPS-IIID reveals considerable interfamilial phenotypic variability. This could be the result of different functional consequences of the various mutations in the GNS gene or to the potential modulating effects of other genes or to differences in genetic backgrounds and possibly even environmental effects, such as intrauterine environment. However, all reported GNS mutations in MPS-IIID to date are protein truncating mutations, including a large intragenic deletion, premature stop codons, frameshift mutations, and a probable RNA splicing mutation. So far, no GNS missense mutation has been found in MPS-IIID, suggesting that a more severe genomic change predicting more severe biochemical deficiency is the underlying cause.
The siblings in family 1 were each homozygous for a single nucleotide change in exon 10, predicting a nonsense mutation at the amino acid level (p.Gln390Ter). Family 1 is the third family with MPS-IIID of Italian origin in whom the molecular defect has been defined. So far, all the families have a different molecular defect underlying the disease. However, since 65% of patients reported to have MPS-IIID are of Italian ancestry, it would be of interest to investigate whether the other Italian patients with MPS-IIID share one of the known mutations, suggesting a common founder.
In family 3, the proband was homozygous for an insertion that is predicted to lead to a frameshift, is likely to cause premature termination at residue 389, and would have 8 abnormal C-terminal residues.
The absence of these mutations from chromosomes of control subjects together with the fact that the truncated products of the mutant alleles would likely be subject to nonsense-mediated messenger RNA degradation argues strongly in favor of disease causality in the case of both mutations.
In family 2, the proband and his healthy mother were each heterozygotes for a common single nucleotide polymorphism in exon 2 of GNS (c.198A/G) (data not shown) and a novel mutation occurring directly in the acceptor splice site in intron 7 (c.876-2A>G). The nature of this likely splicing mutation and its absence from control subjects make it highly probable that it is a disease-related mutation. These findings suggest the existence of a possible second GNS mutation causing the disease in the proband, but so far we have not identified any additional mutations. Such a mutation might be located in the promoter region and might affect transcription, or might be situated deep in an intron and affect splicing, or there might be a large deletion affecting 1 or more exons that may be detectable using multiplex ligation-dependent probe amplification. Further analysis to distinguish between these possibilities is not possible or warranted at present and lies outside the scope of this article.
To date, 7 different mutations have been identified in all 7 families studied (Table). Further mutational analysis in these patients will help clarify genotype-phenotype correlations.
Correspondence: An C. M. Jansen, MD, Department of Pediatric Neurology, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium (email@example.com).
Accepted for Publication: March 13, 2007.
Author Contributions: Dr Jansen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Jansen, Leonard, F. Andermann, and E. Andermann. Acquisition of data: Jansen, Cao, Kaplan, Silver, Leonard, De Meirleir, Lissens, Liebaers, Veilleux, F. Andermann, Hegele, and E. Andermann. Analysis and interpretation of data: Jansen, Lissens, Hegele, and E. Andermann. Drafting of the manuscript: Jansen, Cao, and Hegele. Critical revision of the manuscript for important intellectual content: Kaplan, Silver, Leonard, De Meirleir, Lissens, Liebaers, Veilleux, F. Andermann, Hegele, and E. Andermann. Obtained funding: Jansen, Cao, and Hegele. Administrative, technical, and material support: Jansen, Leonard, Liebaers, Veilleux, Hegele, and E. Andermann. Study supervision: De Meirleir, Lissens, F. Andermann, and E. Andermann.
Financial Disclosure: None reported.
Funding/Support: This study was supported by the Belgische Stichting Roeping/Fondation Belge de la Vocation and the Savoy Foundation for Epilepsy Research (Dr Jansen) and by the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics and the Canadian Institutes of Health Research, the Canadian Genetic Diseases Network, and Genome Canada (Dr Hegele).
Additional Contributions: We thank the families for their courage in living with MPS-III and for their excellent collaboration.